Pituitary adenylate cyclase-activating peptide/vasoactive intestinal peptide receptors in human normal mammary gland and breast cancer tissue

Gynecological Endocrinology

Volumn 20, Issue 6, 2005, Pages 327-333

  García Fernández, M Olga ^a   Collado, Beatriz ^a   Bodega, Guillermo ^a   Cortés, Joaquin ^a   Ruíz Villaespesa, Antonio ^b   Carmena, Maria J ^a   Prieto, Juan Carlos ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

Author keywords

Breast cancer; Human mammary gland; PACAP VIP receptors; VIP receptor antagonists

Indexed keywords

HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE 1 RECEPTOR; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE 27; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE RECEPTOR; MESSENGER RNA; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE 1 RECEPTOR; VASOACTIVE INTESTINAL POLYPEPTIDE 2 RECEPTOR; VASOACTIVE INTESTINAL POLYPEPTIDE ANTAGONIST; VASOACTIVE INTESTINAL POLYPEPTIDE DERIVATIVE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR;

ADULT; AGED; ALTERNATIVE RNA SPLICING; ARTICLE; AUTOCRINE EFFECT; BINDING AFFINITY; BREAST CANCER; CANCER GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKOCYTE; MALIGNANT TRANSFORMATION; PARACRINE SIGNALING; PRIORITY JOURNAL; RECEPTOR BINDING; RECEPTOR DENSITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STROMA; TISSUE DISTRIBUTION; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MAMMARY GLANDS, HUMAN; MIDDLE AGED; RECEPTORS, CELL SURFACE; RECEPTORS, PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; RECEPTORS, PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE, TYPE I; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE, TYPE II; RECEPTORS, VASOACTIVE INTESTINAL POLYPEPTIDE, TYPE I; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 22144467353     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: 10.1080/09513590500098240     Document Type: Article

References (37)

1. Garfinkel L, Boring CC, Heath CW Jr. Changing trends. An overview of breast cancer incidence and mortality. Cancer 1994;74:222-227.
2. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics 1999. CA Cancer J Clin 1999;49:8-31.
3. Polyak K. On the birth of breast cancer. Biochim Biophys Acta 2001;1552:1-13.
4. Allred DC, Mohsin SK, Fuqua SA. Histological and biological evolution of human premalignant breast disease. Endocr Rel Cancer 2001;8:47-61.
5. McGuire WL. Hormone receptors: their role in predicting prognosis and response to endocrine therapy. Semin Oncol 1978;5:428-432.
6. Foekens JA, Portengen H, Van Putten WLJ. Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassay in human breast tumor cytosols. Cancer Res 1989;49:5823-5828.
7. Andò S, De Amicis F, Rago V, Carpino A, Maggiolini M, Panno ML, Lanzino M. Breast cancer: from estrogen to androgen receptor. Mol Cell Endocrinol 2002;193:121-128.
8. Cheung KL, Graves CR, Robertson JF. Tumor marker measurements in the diagnosis and monitoring of breast cancer. Cancer Treat Rev 2000;26:91-102.
9. Volpi A, De Paola F, Nanni O, Granato AM, Bajorko P, Becciolini A, Scarpi E, Riccobon A, Balzi M, Amadori D. Prognostic significance of biologic markers in node-negative breast cancer patients: a prospective study. Breast Cancer Res Treat 2000;63:181-192.
10. Cristofanilli M, Hortobagyi GN. Molecular targets in breast cancer: current status and future directions. Endocr Rel Cancer 2002;9:249-266.
11. Said SI, Mutt V. Peptide with broad biological activity: isolation from the small intestine. Science 1970;169:1217-18.
12. Arimura A. Pituitary adenylate cyclase activating polypeptide (PACAP): discovery and current status of research. Regul Pept 1992;37:287-303.
13. Skakkebaek M, Hannibal J, Fahrenkrug J. Pituitary adenylate cyclase activating polypeptide (PACAP) in the rat mammary gland. Cell Tissue Res 1999;298:153-159.
14. Franke-Radowiecka A. Vasoactive intestinal polypeptide (VIP)-immunoreactive nerve fibres in the mammary gland of the pig. Folia Morphol (Warsz) 2003;62:267-270.
15. García-Fernández MO, Bodega G, Ruíz-Villaespesa A, Cortes J, Prieto JC, Carmena MJ. PACAP expression and distribution in human breast cancer and healthy tissue. Cancer Lett 2004;205:189-195.
16. Laburthe M, Couvineau A. Molecular pharmacology and structure of VPAC receptors for VIP and PACAP. Regul Pept 2002;108:165-173.
17. McCulloch DA, MacKenzie CJ, Johnson MS, Robertson DN, Holland PJ, Ronaldson E, Lutz EM, Mitchell R. Additional signals from VPAC/PAC family receptors. Biochem Soc Trans 2002;30:441-446.
18. Collado B, Gutiérrez-Cañas I, Rodríguez-Henche N, Prieto JC, Carmena MJ. Vasoactive intestinal peptide increases vascular endothelial growth factor expression and neuroendocrine differentiation in human prostate cancer LNCaP cells. Regul Pept 2004;119:69-75.
19. Vaudry D, González BJ, Basille M, Yon L, Fournier A, Vaudry H. Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol Rev 2000;52:269-324.
20. Moody TW, Hill JM, Jensen RT. VIP as a trophic factor in the CNS and cancer cells. Peptides 2003;24:163-177.
21. Reubi JC, Läderach U, Waser B, Gebbers JO, Robberecht P, Laissue JA. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin. Cancer Res 2000;60:3105-3112.
22. Plonowski A, Varga JL, Schally AV, Krupa M, Groot K, Halmos G. Inhibition of PC-3 human prostate cancers by analogs of growth hormone-releasing hormone (GH-RH) endowed with vasoactive intestinal peptide (VIP) antagonistic activity. Int J Cancer 2002;98:624-629.
23. Gespach C, Bawab W, De Cremoux P, Calvo F. Pharmacology, molecular identification and functional characteristics of vasoactive intestinal peptide receptors in human breast cancer cells. Cancer Res 1988;48:5079-5083.
24. Breton P, Mirossay L, Empereur S, Chastre E, De Cremoux P, Calvo F, Gespach C. VIP receptor activity and signal transduction in the cancerous progression of the mammary epithelium. Biomed Res 1992;13(Suppl 2):169-180.
25. Moody TW, Leyton J, Gozes I, Lang L, Eckelman WC. VIP and breast cancer. Ann NY Acad Sci 1998;865:290-296.
26. Moody TW, Dudek J, Zakowicz H, Walters J, Jensen RT, Petricoin E, Couldrey C, Green JE. VIP receptor antagonists inhibit mammary carcinogenesis in C3(1)SV40T antigen mice. Life Sci 2004;74:1345-1357.
27. Dagar S, Sekosan M, Rubinstein I, Onyuksel H. Detection of VIP receptors in MNU-induced breast cancer in rats: implications for breast cancer targeting. Breast Cancer Res Treat 2001;65:49-54.
28. 21)VIP: evaluation of biological activity and localization in breast cancer tumors. Peptides 1998;19:585-592.
29. Moody TW, Czerwinski G, Tarasova NI, Michejda CJ. VIP-ellipticine derivatives inhibit the growth of breast cancer cells. Life Sci 2002;71:1005-1014.
30. García-Fernández MO, Solano RM, Carmena MJ, Busto R, Bodega G, Ruíz-Villaespesa A, Prieto JC, Sanchez-Chapado M. Expression of functional PACAP/VIP receptors in human prostate cancer and healthy tissue. Peptides 2003;24:893-902.
31. Gourlet P, Vertongen P, Vandermeers A, Vandermeers-Piret MC, Rathe J, De Neef P, Waelbroeck M, Robberecht P. The long-acting vasoactive intestinal polypeptide agonist RO 25-1553 is highly selective of the VIP2 receptor subclass. Peptides 1997;18:403-408.
32. Gilman AG. A protein binding assay for adenosine 3′:5′-cyclic monophosphate. Proc Natl Acad Sci USA 1970;67:305-312.
33. Spengler D, Waeber C, Pantaloni C, Holsboer F, Bockaert J, Seeburg PH, Journot L. Differential signal transduction by five splice variants of the PACAP receptor. Nature 1993;365:170-175.
34. López-Otín C, Diamandis EP. Breast and prostate cancer: an analysis of common epidemiological, genetic and biochemical features. Endocr Rev 1998;19:365-396.
35. Cao YJ, Gimpl G, Fahrenholz F. Molecular structure analysis of the pituitary adenylate cyclase activating polypeptide type I receptor from pig brain. Biochim Biophys Acta 1994;1222:432-440.
36. Busto R, Carrero I, Guijarro LG, Solano RM, Zapatero J, Noguerales F, Prieto JC. Expression, pharmacological and functional evidence for PACAP/VIP receptors in human lung. Am J Physiol 1999;277:L42-48.
37. Guijarro LG, Rodríguez-Henche N, García-López E, Noguerales F, Dapena MA, Juarranz MG, Prieto JC. Receptors for pituitary adenylate cyclase-activating peptide in human liver. J Clin Endocrinol Metab 1995;80:2451-2457.